Oncology · ChemotherapyRegulatory Approvalcommercialnear-term

Mylan's Methotrexate Sodium ANDA081235 Receives Abbreviated Approval

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Mylan13 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/20/2026, 12:32:35 PM

Assessment confidence: 79% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Mylan's abbreviated approval for Methotrexate Sodium signifies increased competition in the oncology market, which could lead to pricing pressures and shifts in market share. This development is crucial for pharma strategy teams to assess competitive positioning and potential revenue impacts. Regulatory context from FDA (FDA AP — METHOTREXATE SODIUM (ORIG)) supports the near-term read. Assessment grounded in 30 ranked evidence items (23 high-relevance).

Strategic Assessment

Mylan's entry into the Methotrexate market could impact pricing and market share dynamics for competitors. The strongest clinical anchor is Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Chemotherapy, 8 regulatory and 6 competitive items passed relevance filtering for Mylan.

Competitive Pressure

The most relevant competitive pressure comes from Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small (Bristol Myers Squibb) — sponsor/company relevance (bristol myers squibb). Secondary pressure from U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — METHOTREXATE SODIUM (ORIG) (FDA). Entity match (methotrexate sodium); Regulatory pathway relevance (nda). The approval is already granted, indicating no immediate regulatory hurdles for Mylan, but ongoing compliance will be necessary.

Key Opportunities

The entry of Mylan into the Methotrexate market may lead to reduced prices and altered market dynamics, affecting revenue for existing players. Companies should prepare for potential market share erosion.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in early-stage ER-positive breast cancer, impacting existing therapies.
Upside for Mylan may improve if Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Mylan's entry into the Methotrexate market could impact pricing and market share dynamics for competitors.

What Would Change This Assessment

This becomes more urgent if Monitor Mylan's launch timeline and market uptake of Methotrexate Sodium.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — METHOTREXATE SODIUM (ORIG)
FDAhigh relevance
Entity match (methotrexate sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHOTREXATE SODIUM (ORIG)
FDAhigh relevance
Entity match (methotrexate sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HEPARIN SODIUM PRESERVATIVE FREE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HEPARIN SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HEPARIN SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SODIUM BICARBONATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Other | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Electroacupuncture and Exercise for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source

Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Afatinib Dimaleate ANDA210750
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Dr. Reddy's Venetoclax ANDA214733
Humanexa Signalsmedium relevance
Moderate corpus alignment

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of RNA modifications in cancer translational control.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Repurposing licensed viral vaccines as anti-cancer therapeutics: Turning cold tumors hot.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Mylan
Methotrexate Sodium
existing generic competitors

Commercial impact

medium

The entry of Mylan into the Methotrexate market may lead to reduced prices and altered market dynamics, affecting revenue for existing players. Companies should prepare for potential market share erosion.

Regulatory impact

low

The approval is already granted, indicating no immediate regulatory hurdles for Mylan, but ongoing compliance will be necessary.

What to watch

Monitor Mylan's launch timeline and market uptake of Methotrexate Sodium.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.